Hydroxychloroquine News and Research

RSS

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

A new study from Belgian researchers shows that antiviral drug Favipiravir could have a weak effect against the dreaded novel coronavirus or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as seen in hamster models. However, the study also finds there is no efficacy of the much-touted drug Hydroxychloroquine.

22 Jun 2020

Researchers caution use of chloroquine therapy for patients at higher risk of heart rhythm abnormalities

A patient who met many of the published safety guidelines for chloroquine therapy against COVID-19 was observed to have a very abnormal ECG pattern after treatment began, leading to multiple episodes of torsade de pointes (TdP), a life-threatening arrhythmia in which the lower chambers of the heart beat out of sync with the upper chambers.

18 Jun 2020

KHN’s ‘What the Health?’: SCOTUS, Trump collide over transgender rights

Transgender people have had a head-spinning week. First, the Trump administration issued long-promised rules rolling back the Obama administration's protections against discrimination in health care.

18 Jun 2020

Repurposing immunosuppressants to manage COVID-19

It might seem paradoxical to suggest immunosuppression could play a role in managing COVID-19. The seemingly logical therapeutic option for this disease would be an antiviral.

18 Jun 2020

Low potassium levels in COVID-19 disease

Now a new study by an Italian team of researchers published in June 2020 on the preprint server medRxiv reports that potassium levels are often low in COVID-19 disease, mostly due to the urinary loss of potassium.

17 Jun 2020

Antibiotic X-206 effective against SARS-CoV-2 in vitro

The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.

16 Jun 2020

Life saving drug found for COVID-19 patients on ventilators

Results from Oxford University’s RECOVERY trial into existing drugs for the treatment of COVID-19 has found that dexamethasone reduced deaths by a third in ventilated coronavirus patients and by a fifth in coronavirus patients requiring oxygen. This is the first drug of its kind to be demonstrated to have a significant impact on COVID-19 mortality.

16 Jun 2020

Genetic marker may predispose African Americans to cardiac complications from COVID-19

Nearly one out of every 10 African Americans has a genetic variant that puts them inherently at an increased risk for ventricular arrhythmias and sudden cardiac death.

15 Jun 2020

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

A new study by scientists from the U.S and U.K. and published on the preprint server bioRxiv in June 2020 reports that there is no evidence of efficacy for the drug hydroxychloroquine (HCQ) against infection with SARS-CoV-2 in hamsters or macaque models. This finding does not support the current widespread prophylactic and therapeutic use of HCQ in COVID-19.

14 Jun 2020

Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models

A study on the effects of hydroxychloroquinei n macaques infected with the SARS-CoV-2 virus, , used alone or in combination with azithromycin, have been pre-published on Research Square, after their submission to Nature.

12 Jun 2020

Public health officials face wave of threats, pressure amid coronavirus response

Emily Brown was stretched thin. As the director of the Rio Grande County Public Health Department in rural Colorado, she was working 12- and 14-hour days, struggling to respond to the pandemic with only five full-time employees for more than 11,000 residents. Case counts were rising.

12 Jun 2020

Study initiates hydroxychloroquine clinical trial to prevent COVID-19 in healthy people

Rush University Medical Center has opened enrollment for a new clinical trial investigating whether the drug hydroxychloroquine is better than a placebo in preventing COVID-19 infection in healthy people working in health care settings.

12 Jun 2020

Hydroxychloroquine suppresses 'trained immunity'

A new study published on the preprint server medRxiv in June 2020 shows that the drug hydroxychloroquine (HCQ) suppresses a form of immunity called ‘trained immunity,’ with repercussions for its potential use to treat COVID-19.

11 Jun 2020

Anticardiolipin antibodies and COVID-19

A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.

10 Jun 2020

Tocilizumab in Critical COVID-19 Patients

A new study by scientists at Metro Infectious Disease Consultants and published on the preprint server medRxiv* in June 2020 reports that the cytokine blocker tocilizumab is a useful adjunct to supportive medical care in severe COVID-19, with increased survival and a lower requirement for mechanical ventilation.

10 Jun 2020

GlobalData: Use of hydroxychloroquine as COVID19 treatment continues to be debated

There is no clinical evidence that hydroxychloroquine is effective against COVID19. Some studies using hydroxychloroquine have shown no benefits or even an increase in risk of death, but the number of clinical trials investigating hydroxychloroquine as a primary or secondary intervention continues to expand to determine whether the drug candidate is a key contender as a therapeutic or not, says GlobalData, a leading data and analytics company.

10 Jun 2020

Protease inhibition could help defeat SARS-CoV-2

As the COVID-19 pandemic caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread around the world, many researchers are studying epidemiological models to predict its propagation. As of yet, there are no effective vaccines that could counter the SARS- CoV-2 infection or drugs to treat COVID-19 disease

9 Jun 2020

New guidance for healthcare providers caring for hospitalized COVID-19 patients with diabetes

The COVID-19 pandemic presents new challenges for clinicians caring for infected patients with diabetes, according to new guidance published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

5 Jun 2020

Study provides data on hydroxychloroquine outcomes for COVID-19 patients

A study of electronic medical records from US Veterans Health Administration medical centers has found that hydroxychloroquine--with or without azithromycin--did not reduce the risk of ventilation or death and was associated with longer length of hospital stay.

5 Jun 2020

Antiviral effects for COVID-19: Early is better

A new study by an international team of researchers and published on the preprint server medRxiv* in June 2020 describes the possible reasons for inconsistent or null findings in clinical studies of antiviral drugs to date. It proposes a new approach to decide the sample size in light of its findings.

5 Jun 2020

Hydroxychloroquine News and Research

Favipiravir has weak effect on SARS-CoV-2 and Hydroxychloroquine none at all in hamster model

Researchers caution use of chloroquine therapy for patients at higher risk of heart rhythm abnormalities

KHN’s ‘What the Health?’: SCOTUS, Trump collide over transgender rights

Repurposing immunosuppressants to manage COVID-19

Low potassium levels in COVID-19 disease

Antibiotic X-206 effective against SARS-CoV-2 in vitro

Life saving drug found for COVID-19 patients on ventilators

Genetic marker may predispose African Americans to cardiac complications from COVID-19

Hydroxychloroquine ineffective in animal SARS-CoV-2 infection

Hydroxychloroquine shows no antiviral effect on SARS-Cov-2 in non-human primate models

Public health officials face wave of threats, pressure amid coronavirus response

Study initiates hydroxychloroquine clinical trial to prevent COVID-19 in healthy people

Hydroxychloroquine suppresses 'trained immunity'

Anticardiolipin antibodies and COVID-19

Tocilizumab in Critical COVID-19 Patients

GlobalData: Use of hydroxychloroquine as COVID19 treatment continues to be debated

Protease inhibition could help defeat SARS-CoV-2

New guidance for healthcare providers caring for hospitalized COVID-19 patients with diabetes

Study provides data on hydroxychloroquine outcomes for COVID-19 patients

Antiviral effects for COVID-19: Early is better

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News